Adaptimmune is a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - whether intracellular or surface expressed - for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides in order to target and potentially destroy cancer cells in patients.
Our wholly-owned pipeline of SPEAR T-cell therapies and targets continues to evolve; SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we continue to build a pipeline of proprietary TCR therapeutic candidates: We have identified over 25 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs. We believe these research programs are relevant to a wide range of cancer indications.
We believe our approach will lead to SPEAR therapeutic candidates that have the potential to significantly impact cancer treatment and the clinical outcomes of patients with cancer.